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Abstract
Background: Splenic metastases are very rare and are mostly diagnosed at the terminal phase of the
disease or at the time of autopsy. The cytohistological diagnosis, when done, is made prevalently by
splenectomy. Reports on splenic percutaneous biopsies in the diagnosis of splenic metastasis are
fragmentary and very poor.
The aims of this study are to analyse retrospectively the accuracy, safety and the clinical impact of
ultrasound (US)-guided fine-needle aspiration biopsy (UG-FNAB) in patients with suspected splenic
metastasis.
Methods: A retrospective analysis of 1800 percutaneous abdominal biopsies performed at our institute
during the period from 1993 to 2003 was done and 160 patients that underwent splenic biopsy were
found. Among these 160 patients, 12 cases with the final diagnosis of solitary splenic metastases were
encountered and they form the basis of this report. The biopsies were performed under US guidance using
a 22-gauge Chiba needle. All the patients underwent laboratory tests, CT examination of the abdomen and
chest, US examination of abdomen and pelvis.
Results: There were 5 women and 7 men, median age 65 years (range 48–80). Eight patients had a known
primary cancer at the time of the diagnosis of splenic metastasis: 3 had breast adenocarcinoma, 2 colon
adenocarcinoma, 2 melanoma and 1 lung adenocarcinoma. Four patients were undiagnosed at the time of
the appearance of splenic metastasis and subsequent investigations showed adenocarcinoma of the lung in
2 patients and colon adenocarcinoma in the remaining 2. There was a complete correspondence between
the US and Computed Tomography (CT) in detecting focal lesions of the spleen.
The splenic biopsies allowed a cytological diagnosis of splenic metastasis in all the 12 patients and changed
clinical management in all cases.
Reviewing the 160 patients that underwent UG-FNAB of the spleen we found no complications related to
the biopsies.
Conclusion: These results indicate that UG-FNAB is a successful technique for diagnosis of splenic
metastasis allowing an adequate treatment of the affected patients.
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Background
Clinically evidence of splenic metastasis is very rare and
the metastasis of the spleen is mostly diagnosed at the ter-
minal phase of the disease or at the time of autopsy. How-
ever in last decades with the development of imaging
techniques such as ultrasound (US) and computerized
tomography (CT) the diagnostic approaches of abdomi-
nal organs have changed, since US and CT can easily
detect focal lesions of these organs.
The detection of focal defects in the spleen at US and CT
examination in patients with malignancy may suggest the
presence of metastasis, however US, CT, as well as MR
imaging and radionuclide scans cannot differentiate
metastasis from other splenic lesions such as infections or
lymphoma and a cytological diagnosis can be required
since it may effect therapeutic decisions and prognosis
[1,2]. With the development and refinement of new guid-
ance modalities for percutaneous biopsies, many investi-
gator have reported favourable results with biopsies of
various abdominal organs [3-5], however there have been
only a few reports detailing percutaneous biopsy of the
spleen [6-8]. Most reports on percutaneous biopsy of the
spleen concern malignant lymphomas or abscesses [9-
12], while to our knowledge, reports on solitary splenic
metastasis diagnosed with guided-percutaneous biopsies
are fragmentary or very poor [6,13-16].
The aims of this study were to evaluate the accuracy, safety
and the role of splenic biopsy in the management of
patients with suspected solitary splenic metastasis.
Patients and methods
A retrospective analysis of 1,800 abdominal percutaneous
guided biopsies performed at Medical Oncology and
Hematology Department, Hospital of Piacenza between
1993 and 2003 was done and 160 patients that under-
went splenic biopsy were found. Among these 160 cases,
12 patients with the final diagnosis of solitary splenic
metastasis were encountered and form the basis of this
report. There were not 12 consecutive patients, but
selected cases ultimately proven to be positive for splenic
metastasis. Solitary splenic metastasis was defined as focal
single lesion in the spleen parenchyma.
All the patients underwent laboratory tests, CT examina-
tion of the abdomen and chest, US examination of abdo-
men and pelvis. The diameter of the spleen were
measured with US, the splenic focal lesions were meas-
ured and recorded. Splenomegaly was defined by clinical
examination, when the spleen was palpable and by US
and CT examination when the spleen measured over 13
cm in long axis.
The indication criteria used to perform splenic biopsies in
this set of patients were: a) to perform a definite diagnosis
for undiagnosed patients; b) to establish with certainty
the only site of metastasis; c) to ascertain the progression
in patients with metastatic but stable disease.
The splenic biopsies in the 160 patients were performed as
previously reported [9,10,12], briefly ultrasonically
guided fine-needle aspiration biopsy (UG-FNAB) was
done choosing the most convenient route, avoiding the
pleura and vessels. A 22-gauge Chiba needle was intro-
duced into the focal lesion of the spleen under US guid-
ance using a real-time scanner with a puncturing probe; if
the material obtained was not considered adequate for
diagnosis after a rapid cytologic evaluation by the
cytopathologist present during biopsy as previously
reported [17], the procedure was immediately repeated.
Material aspirated was smeared on slides; Papanicolau
and May Grunwald-Giemsa staining methods were rou-
tinely used on the cytologic smears. The diagnostic evalu-
ation of the specimen was made by an experienced
cytologist, and the confirmation of the diagnoses was
based on histologic sampling, surgery, clinical, US and CT
follow-up of longer than six months.
Conditions necessary to do the biopsy were: informed
consent, prothrombin activity more than 50%, platelet
count higher than 70.000/μl and 12 hours of fasting
before the biopsy. The procedure was done in some
instance on an outpatient basis (2 hours in bed with ice
applied and compressed on the abdominal wall). Twenty-
four hours after the splenic biopsy, US abdominal exami-
nation and a complete blood count were undertaken to
ascertain whether complications had occurred. We check
also for late complications with a contact to patients. Pre-
medication was not given, any complications were
recorded and analgesia given as appropriate.
Results
Disease status, patients characteristics at the time of
biopsy and results of splenic biopsies of the twelve
patients with splenic metastases are listed in table 1.
There were 5 women and 7 men, median age 65 years
(range 48–80). Eight patients had a know primary cancer
at the time of diagnosis of splenic lesion: three had breast
adenocarcinoma, 2 colon adenocarcinoma, 2 melanoma,
1 non small cell lung cancer (adenocarcinoma); the
splenic metastasis was metachronous in all these 8
patients. Four patients were undiagnosed at the time of
the appearance of splenic lesion. Subsequent investiga-
tions showed adenocarcinoma of the lung in 2 patients
(patient number 9 and 10), and colon adenocarcinoma in
two (patient number 6 and 7). Among the 8 patients with
a known primary cancer the splenic lesion was the onlyW
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Table 1: Patients characteristics and results of splenic fine-needle aspiration biopsy
Patients
number
Sex/Age Primary
cancer
Disease status
at the time of biopsy
Presentation US pattern,
Lesion's size, splenic size
Other cancer
localization
Results of
splenic biopsy
Treatment Response
1 F/58 Breast ADC Stable disease Asymptomatic
US detection
Hypoechoic 3.5 cm normal Liver metastasis CT PR
2 F/65 Breast ADC Stable disease Asymptomatic
US detection
Hypoechoic 1.5 cm normal Bone Metastasis CT and RT PR
3 F/70 Breast ADC Solitary splenic recurrence Asymptomatic
US detection
Hypoechoic 2.5 cm normal None Metastasis Splenectomy and CT CR
4 M/65 Colon ADC Solitary splenic recurrence Asymptomatic
US detection
Echogenic 4 cm normal None Metastasis Splenectomy and CT CR
5 F/72 Colon ADC Solitary splenic recurrence Asymptomatic
US detection
Hypoechoic 3.5 cm normal None Metastasis CT and RT CR
6 M/80 Colon ADC Solitary splenic presentation Asymptomatic
US detection
Hypoechoic 3 cm normal None Metastasis Splenectomy and 
surgical treatment of 
colon cancer
CR
7 M/48 Colon ADC Solitary splenic presentation Abdominal 
pain, weight 
loss
Hypoechoic 4 cm normal None Metastasis Splenectomy and 
surgical treatment of 
colon cancer
CR
8 M65 Lung ADC Splenic recurrence Asymptomatic 
US detection
Hypoechoic 2 cm normal None Metastasis CT PR
9 M/57 Lung ADC Solitary splenic presentation Asymptomatic 
US detection
Hypoechoic 2.5 cm normal None Metastasis Splenectomy and 
surgical treatment of 
lung cancer
CR
10 M/76 Lung ADC Solitary splenic presentation Asymptomatic 
US detection
Echogenic with hypoechoic 
halo 6 cm normal
Mediastinal 
lymphonodes
Metastasis CT and RT PR
11 M/44 Melanoma Stable disease Asymptomatic 
US detection
Hypoechoic 4 cm normal Lung and lymphonodes metastasis RT PD
12 F/56 melanoma Stable disease Asymptomatic 
US detection
Hypoechoic 8 cm normal liver metastasis none PD
ADC: adenocarcinoma; CT: chemotherapy; RT: radiotherapy; PR: partial response; CR: complete response; PD; progressive diseaseWorld Journal of Surgical Oncology 2007, 5:13 http://www.wjso.com/content/5/1/13
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site of metastasis in 4 patients (patients number 3, 4, 5, 8),
while in the remaining 4 patients it represented the sign of
progression since these patients, 2 with breast cancer
(patients number 1, 2) and 2 with melanoma (patients
number 11, 12), had metastatic but stable disease at the
time of US evidence of splenic lesion. In the 4 patients
previously undiagnosed the splenic lesion was the iso-
lated site of metastasis in 3 (patients number 6, 7, 9),
while patient number 10 had mediastinal lymphonodes
involvement. The clinical presentation of splenic metasta-
sis was asymptomatic in 11 patients (91.6%) and dis-
closed by radiologic technique during clinical
investigations or follow-up; 1 patient presented abdomi-
nal discomfort, weight loss and fever (patient number 7).
The US pattern of the splenic lesions was hypoechoic in
the majority of the patients (10/12, 83.3%), ecogenic and
ecogenic with hypoechoic halo in the remaining two
patients (16.7%).
The focal lesions of the spleen measured in diameter from
1.5 to 8 cm, the spleen showed normal size in all the
patients.
The total number of patients examined in this study
period with a bioptic verified cancer disease was 1620. All
these patients were evaluated with CT/US and splenic
metastases were identified only in 12 cases, so the inci-
dence of splenic metastases in this cohort of patients was
0.74%.
The splenic biopsies allowed a cytological diagnosis in all
the 12 patients with splenic metastasis and these results
were sufficient to define a specific therapeutic approach in
all the patients. Five patients underwent splenectomy; in
addition three of them were successfully treated with sur-
gery for their primary malignancy: colorectal cancer
(patient number 6 and 7) and non-small cell lung cancer
(patient number 9). Two patients were also treated with
chemotherapy (patients number 3 and 4). The remaining
7 patients received a non surgical treatment: two chemo-
therapy (patients number 1 and 8), three chemotherapy
and radiation (patients number 2, 5 and 10), one radio-
therapy alone (patient number 11) and one patient
received no further treatment since the splenic metastasis
was asymptomatic and the patient showed progressive
disease after a second line of chemotherapy (patient
number 12).
The responses to the treatment were complete remission
in 6 patients (50%), partial response in 4 (33.3%) and
progression in 2 (16.7%).
The other 148 patients (pts) that underwent splenic
biopsy by UG-FNAB showed the following disease: malig-
nant disease 122 patients (non-Hodgkin's lymphoma 112
pts, Hodgkin's disease 10 pts), non malignant disease 26
patients (abscess 11 pts, granulomatosis 5 pts, tuberculo-
sis 6 pts, atypical cyst 4 pts).
To calculate the sensitivity and positive predictive value of
FNAB, the numbers of true-positive (TP), true-negative
(TN), false-positive (FP) and false-negative (FN) results
were recorded (table 2). The malignant FNABs were con-
sidered as true positives (TP) in cases where subsequent
evaluations revealed a malignancy, and they were consid-
ered false positives (FP) when no malignancy was found.
The benign FNAB was considered as a true negative (TN)
if they were confirmed as benign lesions and false negative
(FN) in cases of proven malignancy. From these numbers,
the following statistical values have been calculated: sen-
sitivity in percentage as [(TP/TP + FN) * 100], positive pre-
dictive value (PPV) in percentage as [(TP/TP + FP)* 100]
and overall accuracy as [(TP + TN)/(TP + FP + FN + TN) *
100]. Applying this statistical analysis in all the 160 cases
we found that splenic biopsy showed a sensitivity of
98.4% and a positive predictive value of 99.2%. No com-
plications were recorded.
Discussion
In patients with non-lymphomatous malignancy splenic
metastases are infrequent with an autopsy evidence rang-
ing from 2 to 8% [18,19]. In these patients however evi-
dence of widespread metastatic disease is usually present,
whereas isolated splenic metastases are rare [20]. For this
reasons the diagnostic problem of splenic metastasis has
traditionally been of low clinical impact in oncology
patients. It must be emphasized, as reported by Keogan et
al [2], that with the increased use of immunosuppressive
agents, focal lesions in some patients may be related to
Table 2: Overall results of 160 splenic fine-needle aspiration biopsy.
Results N° Statistical analysis %
True positive (TP) 126 Sensitivity 98.4
True negative (TN) 29
False negative (FN) 2 Positive predictive value (PPV) 99.2
Insufficient 2
False positive (FP) 1 Overall accuracy 98.1
total 160World Journal of Surgical Oncology 2007, 5:13 http://www.wjso.com/content/5/1/13
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infection rather than malignancy. As a result, an increase
in demand for splenic fine-needle aspiration has been
reported from oncology centers [6]. Recently Moham-
madi and Calne described a case with splenic metastasis
and reviewed the cases with solitary splenic metastases
reported in the literature and approximately 50 cases were
found [1].
Approximately 60% of these reported cases appear to be
associated with gynaecologic cancers; in this series the
highest association with solitary splenic metastases is rep-
resented by ovarian and endometrial tumors. Colorectal
cancers also represent an high association (11%) of the
primary tumor sites. Furthermore, the majority of the pri-
mary tumors are of histologic type of adenocarcinoma.
In our series the primary cancers are represented by breast,
3 cases (25%), colon 4 cases (33.3%), lung 3 cases (25%),
melanoma 2 cases (16.6%), and according with the cases
previously reported the most frequent histologic type is
adenocarcinoma: 10 cases (83.3%). Our patients with sol-
itary splenic metastasis reported here differ in some
aspects with the cases previously reviewed [1]: none of our
patients had a palpable splenomegaly compared with 11/
53 (20.8%); in 11 of our 12 patients (91.7%) the splenic
involvement was asymptomatic compared with 40/53
(75.5%) [1].
All our patients were pathologically diagnosed by ultra-
sonically guided fine needle aspiration biopsy, while only
two patients reported in the review of literature were diag-
nosed by fine-needle aspiration [1]. In our series splenec-
tomy was performed only in five patients, and the
remaining seven cases were all, but one (patient number
12 with disease progression), treated with chemotherapy
and/or radiotherapy. Splenectomy was initially planned
in all the 7 patients with isolated splenic metastases, how-
ever two of them refused splenectomy (patients number 5
and 8).
Our results show that splenic metastasis can be success-
fully diagnosed by fine-needle aspiration biopsy. It must
be emphasized that in the 160 patients of our institution
that underwent splenic biopsy, this technique showed a
sensitivity of 98.4% and a positive predictive value of
99.2% without complications. These findings support the
suggestion that this technique is valuable for diagnosis
and may be underused [2,6], since there is a paucity of
North American and European reports concerning FNAB
for splenic focal lesion and above all for metastatic disease
involving the spleen.
Silverman et al [13] reported a series of 11 FNAB of the
spleen in patients with carcinoma (4 patients) or haema-
tological malignancies (7 patients). FNAB confirmed met-
astatic carcinoma in 3 patients, malignancy in additional
3 patients, spleen infections in 3 patients (candida,
aspergillus and abscess) and extensive necrosis in the
remaining patient. Only one hemorrhagic complication
was noted following splenic biopsies.
More recently Caraway and Fanning [6] reported the
results of FNAB performed on 50 patients of whom 40
had a previous diagnosis of malignancy (23 lymphopro-
liferative disorders, 13 carcinomas, 3 melanomas and 1
sarcoma). The cytologic diagnoses included 22 cases pos-
itive for malignancy (10 lymphomas, 9 metastatic carci-
nomas, 2 metastatic melanomas, and 1 sarcoma). No
major complications were associated with the FNAB pro-
cedure, one patient developed a pneumothorax that
resolved spontaneously.
We previously reported the results of splenic fine-needle
tissue-core biopsy on 46 patients with lymphoma and we
concluded that the technique was safe and useful for the
diagnosis, staging, and follow-up of malignant lympho-
mas [10].
More recently we reported the results of a multicenter Ital-
ian study concerning 398 splenic biopsies: on overall
accuracy rate of 98.1% and a low complication rate (no
death cases, less than 1% for major complications, and
5.2% for all complications) were recorded [12]. In the
present series of 160 patients that underwent UG-FNAB of
the spleen, the procedure had a treatment clinical impact
in 155 (96.9%). In the remaining 5 cases there was a delay
in treatment defining because 3 patients showed false
results (1 false positive and 2 false negative in low-grade
NHL) and 2 cases with Hodgkin disease obtained inade-
quate results.
Conclusion
Our findings showing an overall accuracy of 98.1% calcu-
lated on 160 patients, without complications, are favour-
able compared with the remaining literature
[2,6,8,12,13]. It must be emphasized that the correct diag-
nosis of the focal splenic lesions is becoming an impor-
tant issue in both undiagnosed and diagnosed patients,
due to same emerging factors such as the improvement in
to the ability of diagnosing imaging techniques to detect
parenchymal focal lesions and prolonging of life expect-
ancy in patients with malignant lymphomas and some
solid tumor. Therefore, the indications for splenic biopsy
are expanding and our results reported here show that
UG-FNAB of the spleen is an effective, safe and cheap
technique for a definite pathological diagnosis.
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